Wells Fargo & Company Upgrades Regulus Therapeutics (NASDAQ:RGLS) to Overweight
Wells Fargo & Company upgraded shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) from an equal weight rating to an overweight rating in a report issued on Thursday, MarketBeat Ratings reports. They currently have $6.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $3.00. RGLS has been the subject […]
Wells Fargo & Company upgraded shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) from an equal weight rating to an overweight rating in a report issued on Thursday, MarketBeat Ratings reports. They currently have $6.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $3.00. RGLS has been the subject […]
